Skeletal muscle enhancer interactions identify genes controlling whole-body metabolism.
Kristine WilliamsLars Roed IngerslevJette Bork-JensenMartin WohlwendAnn Normann HansenLewin SmallRasmus Ribel-MadsenArnie AstrupOluf PedersenJohan AuwerxChristopher Thomas WorkmanNiels GrarupTorben HansenRomain BarresPublished in: Nature communications (2020)
Obesity and type 2 diabetes (T2D) are metabolic disorders influenced by lifestyle and genetic factors that are characterized by insulin resistance in skeletal muscle, a prominent site of glucose disposal. Numerous genetic variants have been associated with obesity and T2D, of which the majority are located in non-coding DNA regions. This suggests that most variants mediate their effect by altering the activity of gene-regulatory elements, including enhancers. Here, we map skeletal muscle genomic enhancer elements that are dynamically regulated after exposure to the free fatty acid palmitate or the inflammatory cytokine TNFα. By overlapping enhancer positions with the location of disease-associated genetic variants, and resolving long-range chromatin interactions between enhancers and gene promoters, we identify target genes involved in metabolic dysfunction in skeletal muscle. The majority of these genes also associate with altered whole-body metabolic phenotypes in the murine BXD genetic reference population. Thus, our combined genomic investigations identified genes that are involved in skeletal muscle metabolism.
Keyphrases
- skeletal muscle
- insulin resistance
- genome wide
- copy number
- type diabetes
- transcription factor
- genome wide identification
- metabolic syndrome
- weight loss
- dna methylation
- fatty acid
- high fat diet induced
- binding protein
- adipose tissue
- cardiovascular disease
- bioinformatics analysis
- gene expression
- glycemic control
- rheumatoid arthritis
- weight gain
- circulating tumor
- blood glucose
- risk assessment
- nucleic acid
- sewage sludge